更早使用免疫预防可提高阻断乙肝母婴传播的保护效果
该前瞻性多中心观察研究纳入1140例HBV感染孕妇所生婴儿,在出生后1小时内给予HBIG和首剂乙肝疫苗,982名婴儿随访至9.6±1.9月龄。总体母婴传播率为0.9%(9/982),HBeAg阴性母亲婴儿为0%,HBeAg阳性母亲婴儿为2.4%(9/375),9例感染婴儿母亲HBV DNA均>2.75×10^6 IU/mL。
要点
- 出生后1小时内给予HBIG和乙肝疫苗,总体母婴传播率0.9%。
- HBeAg阴性母亲所生婴儿无HBV感染,HBeAg阳性母亲婴儿感染率2.4%。
- 母亲HBV DNA>2×10^6 IU/mL是免疫预防失败的独立危险因素。
核心结论
- 出生后1小时内使用HBIG和乙肝疫苗可提供更好的阻断HBV母婴传播保护效果。
研究设计与样本
- 前瞻性多中心观察研究,纳入1140例HBV感染孕妇,982名婴儿随访至9.6±1.9月龄。
主要发现
- 总体母婴传播率为0.9%(9/982)。
- HBeAg阴性母亲所生607名婴儿中0%感染HBV。
- HBeAg阳性母亲所生375名婴儿中9名(2.4%)感染HBV。
- 9例感染婴儿母亲HBV DNA均>2.75×10^6 IU/mL。
- 母亲HBV DNA>2×10^6 IU/mL是免疫预防失败的独立危险因素(OR 10.627,95%CI 2.135-∞)。
关键数值与推荐
- HBIG和首剂乙肝疫苗在出生后中位0.17(0.02-1.0)小时内给予。
临床怎么用
- 对HBV感染母亲所生婴儿,应尽早(出生后1小时内)给予HBIG和首剂乙肝疫苗。
- 对HBV DNA>2×10^6 IU/mL的母亲所生婴儿需关注免疫预防失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Passive-active immunoprophylaxis against mother-to-child transmission (MTCT) of hepatitis B virus (HBV) recommends administering hepatitis B immunoglobulin (HBIG) and birth-dose hepatitis B vaccine in infants within 12 or 24 hours after birth. With this protocol, MTCT of HBV still occurs in 5-10% infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg). The present study aimed to investigate whether earlier administration of HBIG and hepatitis B vaccine after birth can further increase protection efficacy. METHODS: We conducted a prospective, multi-center observational study in infants born to mothers with HBV infection, in whom neonatal HBIG and birth dose hepatitis B vaccine were administered within one hour after birth. The infants were followed up for HBV markers at 7-14 months of age. RESULTS: A total of 1140 pregnant women with HBV were enrolled, and 982 infants (9 twins) of 973 mothers were followed up at 9.6 ± 1.9 months of age. HBIG and birth-dose vaccine were administered in newborn infants within a median of 0.17 (0.02-1.0) hours after birth. The overall rate of MTCT was 0.9% (9/982), with none (0%) of the 607 infants of HBeAg-negative mothers and 9 (2.4%) of 375 infants of HBeAg-positive mothers acquiring HBV. All 9 HBV-infected infants were born to mothers with HBV DNA >2.75 × 106 IU/mL. Maternal HBV DNA levels >2 × 106 IU/mL were an independent risk factor (odds ratio, 10.627; 95% confidence interval, 2.135-∞) for immunoprophylaxis failure. CONCLUSIONS: Earlier use (within 1 hour after birth) of HBIG and hepatitis B vaccine can provide better protection efficacy against MTCT of HBV.
引用
- Huang H, Xu C, Liu L, et al. Increased Protection of Earlier Use of Immunoprophylaxis in Preventing Perinatal Transmission of Hepatitis B Virus. Clin Infect Dis. 2021. PMID: 32634824. doi:10.1093/cid/ciaa898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。